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Abstract: The worldwide epidemic of obesity has become an important public health issue,
with serious psychological and social consequences. Obesity is a multifactorial disorder in which
various elements (genetic, host, and environment), play a definite role, even if none of them
satisfactorily explains its etiology. A number of neurological comorbidities, such as anxiety and
depression, charges the global obesity burden, and evidence suggests the hypothesis that the brain
could be the seat of the initial malfunction leading to obesity. The gut microbiome plays an important
role in energy homeostasis regulating energy harvesting, fat deposition, as well as feeding behavior
and appetite. Dietary patterns, like the Western diet, are known to be a major cause of the obesity
epidemic, probably promoting a dysbiotic drift in the gut microbiota. Moreover, the existence of a
“gut–brain axis” suggests a role for microbiome on hosts’ behavior according to different modalities,
including interaction through the nervous system, and mutual crosstalk with the immune and the
endocrine systems. In the perspective of obesity as a real neuropsychological disease and in light of
the discussed considerations, this review focuses on the microbiome role as an emerging director in
the development of obesity.
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1. Introduction
Obesity is an abnormal or excessive fat mass accumulation that affects the health status.
The worldwide epidemic of obesity has become an important public health issue, with serious
psychological and social consequences since, worldwide, over 650 million adults and 340 million
children and adolescents are obese [1]. Obese phenotypes can be associated with some genetic
predispositions [2,3] and with sedentary lifestyle. However, these factors alone fail to accurately
describe and explain the complexity of the phenomenon. Obesity is a multifactorial disorder which
is a result of the interaction of host and environmental factors and its prevalence in high income
and upper middle-income countries is more than double that of low and lower middle income
countries [4]. Because of that, it constitutes a social problem, especially in those upper middle-income
countries, not just affecting the welfare state, but also creating issues in terms of social relations and
acceptance, and personal development. Moreover, obesity is considered, sometimes erroneously, as the
consequence of an unbalanced and/or mistaken feeding conduct. On the contrary, recent long-term
studies reveal a more complex scenario, including neuropsychological and neurobiological factors [5],
that in turn involve not only a different categorization of the pathology itself but also suggest that
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obesity cannot be adequately treated through simple nutritional plans, associated with training and
exercise [6]. By considering the complex nature of the pathology (from genetic factors to behavioral
and social ones) and given the poor effectiveness of many pharmacological and nutritional approaches,
some researchers suggest that “behavioral dimension” should not be neglected, in order to develop
new approaches, both preventive and therapeutic, that include obesity within neuropsychological
syndromes [5].
In the last years, increasing evidence suggests that microbiome can have a strong impact on
hosts’ behavior by different modalities, including interaction through the nervous system, mutual
crosstalk with the immune and the endocrine systems, and finally with direct synthesis and managing
of neuro-chemicals [7–10]. In detail, it is well known that the microbiome plays a crucial role in the
“gut–brain axis” homeostasis [11], affecting this bidirectional neurohumoral communication, through
the production of neuroactive molecules and regulating the circulating levels of some cytokines.
Studies have demonstrated that some bacterial strains and their metabolites might target the brain
directly, via vagal stimulation, or indirectly through immune-neuroendocrine mechanisms, triggering
pro-inflammatory cytokines production and causing neuroinflammation [12]. Given the role of gut
microbiome also in energy homeostasis [13,14], it is critical to connect, in a more consistent scenario,
the findings relative to metabolic disorders with those concerning neurological and neuropsychological
diseases, in the light of general microbiome activities. For instance, dietary patterns, like Western
diet, are known to be a major cause of the obesity epidemic, probably promoting a dysbiotic drift in
the gut microbiota (GM) [15]. In fact, obese subjects often show neurological comorbidities, such as
deficits in memory, learning and executive functions, anxiety and depression, and some evidences
support the hypothesis that the brain could be the seat of the initial malfunction leading to obesity [11].
Moreover, by increasing systemic inflammation, microglial activation and affecting vagal nerve activity,
the microbiome can indirectly influence hypothalamic gene expression and promote overeating [12].
Given that microbiome acts and connects different host regions, being involved in many physiological
and pathological conditions, this review will focus on GM role as emerging director in the obesity
pathogenesis and related neurological conditions. As data source, we used Google Scholar and
PubMed databases for English-language published material (from 1 January 2008 to 30 August
2018) and examined review and original research articles, using a combination of keywords such as
microbiota, microbiome, obesity, neurologic diseases, nervous system, cognitive impairment, gut brain
axis, and inflammation. We used our judgment to select articles, sum evidences, and interpret results.
2. Why a Neuropsychological View of Obesity?
Obesity occurs when energy intake exceeds energy expenditure over time, and, traditionally, it is
considered as the consequence of a sedentary lifestyle and the usual excessive food consumption.
Excessive adiposity is a major risk factor for cardiovascular disease, cancer, type 2 diabetes,
and mood-related disorders, with obese individuals often suffering social stigmatization [16,17].
Given its multifactoriality, the obesity is a complex disease in which both genetic and environmental
factors play a role in its development. Anyway, none of them satisfactorily explains the etiology
yet and many details of this pathological condition remain murky. Since differences in the brain
could be both a consequence of, and/or an explanatory factor for obesity, recent attention has shifted
towards its neurobiological features, in particular in the pathogenic processes and in the clinical-related
neurological conditions.
2.1. Neurobiological Aspects of Obesity’s Pathogenesis
Feeding, appetite, and energy expenditure are under the control of the central nervous system
(CNS), which receives various peripheral signals of energy status and its availability, such as gut
hormones and adipokines (signaling molecules released by the adipose tissue) [18,19]. In particular,
the hypothalamus regulates the homeostatic feeding behavior, while other neural brain regions,
such as insular cortex, orbitofrontal cortex, nucleus accumbens, amygdala, and dopaminergic ventral
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tegmental area, present groups of neurons implicated in the reward-related non-homeostatic control of
feeding [20].
Besides the role of orexigenic hormones, like ghrelin [21], and neuropeptides, such as
agouti-related protein or neuropeptide Y (activated in hypothalamic neurons during fasting) [22],
the food intake is mainly regulated by the energy need from brain, based on its adenosintriphosphate
(ATP) disposability [23]. This is possible thanks to the brain regulation of systemic-metabolic pathways.
Indeed, an hyperinsulinemic-hypoglycemic state, caused by energy-deficiency, induces the activation
of ATP-sensitive K+ channels (KATP channels) in the hypothalamus, leading to the increase in hunger
feelings, to the gluconeogenesis stimulation, the activation of stress system, and the reduction of
pancreatic insulin release [23,24]. First, dysfunctions in any part of this metabolic pathway, such as
congenital leptin deficiency, can result in a persistent state of positive energy balance and the obesity
development [25,26]. Moreover, it has also been suggested that an alteration in glucose allocation to
the brain, keeps the hypothalamic appetite centers activated, engendering a persistent stimulus to
food intake, thus causing obesity over time [27,28]. The fact that the brain energy content negatively
correlates with BMI (body mass index), supports the viewpoint that the brain can regulate body mass
by changing the intake of foods, eventually crucially contributing to the obesity pathogenesis [29].
In addition, the observation that cerebral ATP and phosphocreatine (PCr) levels predict the amount of
calories subsequently consumed [30], supports this interpretation. Interestingly, recent studies seem to
suggest that alterations in cerebral energy homeostasis may lead to enhanced food intake behavior and,
in the long term, to obesity itself [31]. Other investigations have observed, in obese subjects, chronic
neuro-energetic deficiency, and lack of satiety perception [32].
In addition to the homeostatic metabolic systems, food intake is regulated by the reward-related
mechanisms, through the mesolimbic dopamine (DA) pathways [33], and by stress axis activity [34].
The stress response occurs through the HPA (hypothalamic-pituitary-adrenal) axis [35] activation that
ends with the cortisol secretion.
The mesolimbic pathway is a dopaminergic pathway in the brain that connects the ventral
tegmental area in the midbrain, to the ventral striatum of the basal ganglia in the forebrain. The DA
release plays a role in the pleasure perception and any dysregulation of this process can be linked to
the development and maintenance of an addiction [36]. In general, palatable energy-dense foods are
often consumed even after energy requirements have been met, and the immoderate consumption of
tasty hypercaloric food can lead to a profound state of reward hyposensitivity that is similar to that
of drug abuse, leading to the development of compulsive-like eating behaviors [36]. Because of this
mechanism, the wide availability of tasty junk food is considered as the major environmental risk
factor for obesity [37]. Moreover, stress, triggering DA release [38,39], renders people susceptible to
substances that, via reward processing, motivate individuals to overconsumption [40]. At the same
time, eating highly pleasant foods further affects reward processing to augment the stress-eating
cycle [41,42]. In fact, through negative reinforcement [34], the so-called “comfort food” provides relief
from a stressful states, and the hedonic withdrawal that occurs because of the long-term exposure
to cortisol [43], is then ingrained as reward-driven habits [44]. Hence, persistent period of stress,
that chronically activate the dopaminergic reward system, leads to the development of addiction-like
behavior and the beginning of a vicious circle [6] and any decrease in dopamine concentration results
in intake of comfort foods, which, in the long time, can drive the weight gain. Finally, among its various
functions, cortisol triggers processes that lead to weight gain [45], promoting obesity essentially in two
ways. In primis, it is able to increase eating [46,47], by reducing the brain’s sensitivity to leptin [41],
regulating neuropeptide Y (NPY) stimulation [48], or strengthening reward pathways [39]. Second,
it promotes fat deposition, especially in the abdominal region [49,50] (of note: abdominal obesity
represents a marker for longterm cortisol levels) [51]. Indeed, chronic stress enhances food intake,
engendering an HPA axis’ hyper activation that leads to the obesity evolution. Hence, obesity can be
in part explained by the dysregulation of fundamental neurobiological mechanisms, which lead to
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irregular eating behaviors, and the interconnection between metabolic disturbances and psychological
aspects must be still elucidated.
2.2. Obesity and Neurological Comorbidities
Clinical studies indicate an association between obesity and neurological disorders, concerning
both the central and peripheral nervous system (Table 1).
The net energy overload observed in obese patients, leads to the increase in the adipose mass,
characterized by adipocytes hypertrophy and/or hyperplasia, which is necessary for the storage of
surplus calories. The expansion of the adipose tissue contributes to its dysregulation that includes an
altered adipokine secretion profile, the activation of resident macrophages and the establishment a low
grade metabolic inflammation (Figure 1).
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the CNS, neuroinflammation and lipotoxic FFA can lead to dementia, cognitive impairment, anxiety, 
and depression, whereas in the PNS the end result are peripheral neuropathies. FFA = free fatty acids. 
CNS = Central nervous system. PNS = peripheral nervous system. 
In particular, adipose tissue alteration is characterized by the production of: pro-inflammatory 
cytokines interleukin-1Beta (IL-1Beta), IL-6, tumor necrosis factor-alfa (TNF-alfa), monocyte 
chemotactic protein 1 (MCP-1) [52]; inflammatory mediators C-reactive protein and leptin [53] and 
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A dysbiotic microbiota contributes to the leaky gut syndrome, allowing the translocation of gut peptides
and bacterial products that increase the peripheral inflammatory tone inducing neuroinflammation.
In addition, the dysfunctional obese adipose tissue lead to the increased circulation of inflammatory
cytokines, adipokines and FFA. FFA, beside the action on peripheral tissue, where they contribute
to the establishment of a metabolic syndrome, have a detrimental effect on both the CNS and PNS.
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In particular, adipose tissue alteration is characterized by the production of: pro-inflammatory
cytokines interleukin-1Beta (IL-1Beta), IL-6, tumor necrosis factor-alfa (TNF-alfa), monocyte
chemotactic protein 1 (MCP-1) [52]; inflammatory mediators C-reactive protein and leptin [53] and
increased release of free fatty acids (FFA) [54]. The circulating FFA exert a lipotoxic effect on peripheral
and nervous tissues, being responsible for the establishment of a metabolic syndrome and the onset of
neurological diseases [55,56]. In detail, FFA can target both the CNS and the peripheral nervous system
(PNS), leading to cognitive impairment, other CNS diseases and peripheral neuropathies [56–58].
Epidemiological and prospective studies show that obesity increases the risk of mild cognitive
impairment [59–63], Alzheimer’s disease and dementia [64,65]. Moreover, a high BMI is associated
with episodic memory deficits [66], altered decision making [67], attention-deficit/hyperactivity
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disorder [68–70], learning and memory problems [71] both in adults and adolescents [72,73]. In obese
patients, the establishment of a low grade inflammation and the altered FFA metabolism seems
to provoke structural changes in the brain, such as the reduction of hippocampal volume [74]
and the atrophy of frontal, temporal and subcortical regions [75], as well as impaired executive
functions [76–78]. In response to the increase of dietary fat, inflammation and metabolic dysfunctions
affect the brain, in particular the hippocampus, an essential structure for learning and memory,
and susceptibility to aging-related atrophy [78,79]. For example, FFA and triglycerides can directly
alter hippocampus functions [78], and circulating adipokines provoke an alteration of the blood–brain
barrier (BBB) permeability [79]. The latest mechanism establishes a feed-forward cycle of injury, since
the unruly entrance of pro-inflammatory cytokines and chemokines, immune cells [80] and FFA into
the hippocampus, engenders neuroinflammation, promoting neurodegeneration [81,82]. Moreover,
the insulin-resistance associated with a high fat (HF) diet affects microvascular perfusion in the
hippocampus, decreasing cognitive function in rodents [83]. In addition, the hypothalamus, which is
not protected by the BBB, is particularly vulnerable to circulating lipotoxic fats and adipokines [84].
The hypothalamic inflammation occurs early in response to a HF diet feeding and induces microglial
and astrocyte reactivity [84] with the gliosis promotion and the propagation of pro-inflammatory
signaling [85]. Finally, the HF diet leads to the apoptosis of hypothalamic neurons [86] linked to
the pathogenesis of Alzheimer’s disease. Additionally, metabolic disturbances in obesity affecting
the HPA axis regulation, can further worsen depression [87], a condition commonly associated with
obesity [88,89].
The pathophysiological consequence of obesity also affects the PNS. First, the autonomic
ganglion and postganglionic fibers are not protected by BBB and susceptible to obesity-mediated
inflammation [90]; second, sensory neurons and peripheral sensory receptors lie out of the blood–nerve
barrier, being exposed to metabolic insults [91]. Recent evidence suggests that obesity is a risk factor
for the development of autonomic neuropathy and polyneuropathy, a distal-to-proximal loss of
sensory perception [92–95]. This can be due to the chronic dysfunction secondary to obesity and
lipid-induced inflammation and it is characterized by the accumulation of macrophages and the
expression enhancement of the pro-inflammatory cytokines in peripheral nerves [96,97]. Interestingly,
various findings, obtained in human beings and in animal models, show that dietary intervention,
bariatric surgical procedures and the resolution of obesity improve polyneuropathy, decreasing
neuropathic pain [98], and ameliorate the cognitive performances [99–102].
Despite all these studies, the fine mechanisms linking obesity to cognitive and neurological
disorders still need to be elucidated. Even if inflammation plays a prominent role in the development
of neurological dysfunction, additional research should be focusing on the identification of new
pathways linked to obesity-related inflammation, such as the gut–brain axis communication.
Table 1. Clinical studies showing an association between obesity and central nervous or peripheral
neurological diseases.
Study Sample Size Patients’ Features Findings Ref.
Central nervous system disorders
Holtkamp
et al., 2004 97 men
Children with
attention-deficit/hyperactivity
disorder (ADHD)
Obesity development independent of
ADHD diagnosis [69]
Elias et al.,
2005
551 men, 872
women
Individuals with healthy body weight,
overweight, obese
In men, obesity association with adverse
cognitive effects [59]
Cournot et al.,
2006
1660 men, 1576
women Healthy workers (32–62 years old)
Higher BMI association with lower
cognitive scoresand higher cognitive
decline
[60]
Boeka et al.,
2008 20 men, 48 women
Caucasian and African American
extremely obese patients
Evidence of specific cognitive
dysfunction in extremely obese
individuals
[73]
Sabia et al.,
2009
3788 men, 1343
women White individuals Multiple effects of obesity on cognition [61]
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Table 1. Cont.
Study Sample Size Patients’ Features Findings Ref.
Central nervous system disorders
Hassing et al.,
2010
140 men, 277
women Swedish twin registry
Midlife overweight association to lower
overall cognitive function in old age [62]
Anstey et al.,
2011 71529 individuals
Participants evaluated for any type of
dementia
Overweight and obesity in midlife
increase dementia risk [64]
Dahl et al.,
2013
280 men, 377
women
Swedish adoption and twin study of
ageing
Midlife overweight or obesity responsible
of lower cognitive function and cognitive
decline in late life
[63]
Yau et al.,
2014
30 obese, 30 lean
adolescents
Obese without insulin resistance or
metabolic syndrome
Uncomplicated obesity may result in
subtle brain alterations [72]
Cheke et al.,
2016 14 men, 36 women
8 Obese individuals, 16 overweight,
26 lean
Higher BMI association with lower
performance on the what-where-when
memory task
[66]
Navas et al.,
2016 35 men, 44 women
38 Normal weight, 21 overweight, 20
obese
Obesity is linked to a propensity to make
risky decisions [67]
Kummer
et al., 2016
92 patients and 19
controls
Children and adolescents: autism
spectrum disorder (ASD) andADHD
Higher risk of overweight and obesity in
ASD and ADHD [70]
Peripheral nervous system diseases
Ylitalo et al.,
2011
2514 adults aged ≥
40 years
Individuals with peripheral
neuropathy,peripheral vascular
disease (PVD), alower-extremity
diseases (LEDs).
Obesity and cardiometabolic clustering
markedly increased the likelihood of
LEDs
[92]
Tesfaye et al.,
2005 1172 patients Patients with type 1 diabetes mellitus.
Higher BMI independently associated
with the incidence of neuropathy. [93]
Ziegler et al.,
2008
195 patients and
198 controls
Population-based MONICA/KORA
Augsburg Surveys aged 25–74 years.
Waist circumference association with
peripheral arterial disease (PAD) [94]
Singleton
et al., 2014
21 obese, 51 lean
controls
Non-diabetic obese patients referred
for Roux en Y bariatric surgery
compared with lean controls.
Asymptomatic neuropathy is common in
very obese patients independent of
glucose control
[95]
3. The Microbiota–Gut–Brain Axis
The intestine and the brain are intimately connected by the gut–brain axis, a complex bidirectional
system in which the central and enteric nervous system communicate involving endocrine, immune
and neuronal pathways. Communication and functions of this axis are regulated by the GM at the
point that the concept of microbiota–gut–brain (MGB) axis has been introduced to underline the pivotal
role of GM in the development of metabolic and neurological diseases.
The microbiota represents the community of microbes (bacteria, archaea, viruses, and fungi) that
reside in a particular habitat (e.g., the gut microbiota) and establish with the host a mutually beneficial
relationship (while the “microbiome” represents the collective genomes of microorganisms) [103].
In particular, the microbiota offers benefits to the host maintaining the gut integrity [104], harvesting
energy [105], providing protection against pathogens [106] and regulating the immune system [107].
The human gastrointestinal tract holds more than 1000 bacterial species, mainly located within
distal ileum and colon, which belong prevalently from Bacteroidetes and Firmicutes phyla. The GM
com-position is highly dynamic and susceptible to rapid changes in response to external factors as
diet, stress, smoking, infections, or perturbation of the healthy state [108]. In turn, changes in GM
com-position and function, named dysbiosis, can be responsible for the development of various
diseases (e.g., colorectal cancer) [109,110], and, can contribute to the disruption of the molecular
dialogue between gut and brain [111].
The MGB axis is composed of the CNS, the autonomous nervous system (ANS), the neurons of the
enteric nervous system (ENS), the HPA-axis and the GM. In particular, signals from the brain influence
the motor, sensory, and secretory modalities of the gastro-intestinal tract, regulate the inflammatory
process and influence the GM structure [112]. In turn, visceral messages from the gastro-intestinal
trait can influence brain function [112,113]. For instance, under stress conditions, the cortisol released
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following HPA axis activation alters the gut permeability and barrier function, thus affecting the GM
composition [112].
Conversely, the gut microbiome influences the brain functions modulating the levels of various
brain transmitters (i.e., serotonin) [114] and circulating cytokines, that can exceed the BBB [115,116].
Growing evidence, involving studies in germ-free (GF) animal models, which intestinal flora is
missing from birth, and humans exposed to probiotic agents or antibiotics, suggests that several
pathologic conditions may be affected by a MGB axis dysregulation, such as autism spectrum
disorders [117–119], anxiety/depression [120], and obesity [121–123].
3.1. Microbiome and Energy Harvest
The intestinal microbiome plays a key role in digestion and absorption of nutrients, regulating
energy homeostasis through different mechanisms as energy extraction from food and the modulation
of fat storage by the short chain fatty acids (SCFAs) and monosaccharides absorption.
The first information about the role of bacterial flora in the obesity physiopathology was obtained
in GF mouse models [124–126]. These mice were significantly leaner than controls, despite introducing
more calories from food [127]. Moreover, GF mice showed modified plasma fatty metabolic markers
and lower amount of leptin and ghrelin, suggesting an energy imbalance [128]. When GF mice were
transplanted with gut bacterial flora obtained from conventionally raised mice, they showed an
increase in insulin resistance and in body fat without an observed increment in nutrient intake [123].
This evidence has placed the gut microbiome at the center of a completely new research field,
concerning the pathophysiology of obesity. Biochemical and metagenomics data analysis suggested
that the “obese microbiota” [14] was able to harvest more energy from the diet and this ability was
also transferable. Thus, the colonization of GF mice with an obese microbiota (human or murine)
induced an increase in total body fat higher than that one obtained through colonization with a lean
microbiota [129]. In addition, when eutrophic GF mice received fecal microbiota from obese women,
metabolic complications associated to obesity have been observed [130]. This evidence indicates how
rapid, transmissible and flexible can be the relation between food and commensal microorganisms in
obesity and metabolic syndrome.
Animal obesity models and obese humans present a similar microbial phylum taxonomic rank
dysbiosis. In particular, humans and mice share two main phylum: Firmicutes and Bacteroidetes;
an alteration of Firmicutes/Bacteroidetes ratio was observed in several obesity studies in both mice [131]
and humans [14]. Indeed, the Firmicutes could break down indigestible carbohydrates and converting
them into absorbable energy products [132–134]. However, in a meta-analysis study the observed
alteration in the ratio Firmicutes/Bacteroidetes seemed to be unrelated to weight differences [135]. Also,
the reduction in microbial diversity and alteration of particular microbial families or species have been
observed in obesity conditions [114], such as the increase of Proteobacteria [136].
The complex interplay between host genetics, gut microbiome and environmental factors is crucial
for the obesity pathophysiology (for instance, monozygotic twins showed a more similar GM profile
than did dizygotic twins) [137]. Dietary pattern could also affect the bacterial structure, for example,
westernized diets increase the abundance of Clostridia (Firmicutes phylum) populations that could
extract more energy from the diet, consenting higher energy utilization [138]. The unused extra energy
is then accumulated as fat deposits.
While different processes, by which an “obese microbiota” can affect body weight
balance [127,139,140] have been indicated, the increased energy harvest via colonic fermentation
and SCFAs’ production is the most direct [14]. Bacterial enzymes (specific glycoside hydrolases)
metabolize otherwise not digested by humans food components, like vegetable fibers (such as resistant
starch, cellulose, and inulin) that cannot be metabolized by human enzymes. The final product of
this process are energy-rich substrates, such as SCFAs [141]. SCFAs can provide ≤10% of total daily
caloric intake [142]. Obese individuals show significantly increased levels of SCFAs such as acetate,
propionate, and butyrate [133,143]. Most of the bacterial SCFAs (in particular butyrate) are derived
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from the fermentation process of Clostridia cluster [144]. SCFAs not only operate as energy substrates for
host tissues and bacteria but also act as signaling molecules in the host metabolism, showing a relevant
role in mediation of gut motility, regulation of fat storage and appetite [105]. Indeed, dysbiosis induced
by the type of diet has been correlated with an acetate increase that promotes hyperinsulinemia [145].
Furthermore, SCFAs can influence other obesity-associated conditions such as insulin resistance and
hyperglycaemia [146].
Among the SCFAs, the propionate can be utilized locally through conversion into glucose by
intestinal gluconeogenesis or diffuse into the portal vein to be utilized as a substrate for hepatic
gluconeogenesis, preventing high SCFAs concentrations in blood [147]. In addition, propionate
decreases human lipogenesis and serum cholesterol (in hepatic and non hepatic tissues) [148], and also
reduce the fasting blood glucose and hepatic cholesterol in obese rats [149].
In addition, several studies shows acetate benefits on metabolism. Acetate could bind to the
receptor GPR43 in several target organs. In adipose tissue, the GPR43 activation inhibits insulin
signaling and suppresses fat accumulation, while systemically, it improves insulin sensitivity [150].
Mice deficient in the acetate receptor GPR43 become obese when fed a normal diet, whereas mice who
overexpress GPR43 remain lean even when fed an obesogenic diet [150]. In the liver, acetate reduces
lipid accumulation and improves liver function and mitochondrial efficiency. In adipose tissue, acetate
inhibits fat breakdown but induces the browning of white adipose tissue and metabolic improvements,
leading to a reduction in body fat [151]. Finally, prebiotics such as inulin, increased acetate production
that crosses the blood–brain barrier of rats and results in reduced grehlin production and so, inducing
a decrease of body weight, food intake, and fat mass [152]. Moreover prebiotic fructooligosaccharides
increase acetate production, reducing body weight and fat mass because it favors a lower food intake
in mice [153].
Microbial metabolites can also regulate the composition of bile acid species. A reduced bile acid
amount in the intestine has been associated with inflammation and microbiota overgrowth [154].
Some intestinal bacteria are able to extract energy from the metabolization of bile acids, inducing the
activation of bile acid receptors farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor
5 (TGR5). These two receptors maintain insulin sensitivity and glucose tolerance in both liver and
intestine [29,30]. In addition, other mechanisms have been proposed to account for the increased
microbiota capacity to extract energy from the diet intake [155]:
1. GM influences energy homeostasis by regulating gene expression via complex mechanisms
started by SCFAs and monosaccharides [156]. In particular, the commensal microorganisms
stimulate monosaccharide cellular uptake [157] and induce lipogenesis by activating the
transcription factors carbohydrate response element binding protein (ChREBP) and sterol
response element binding protein (SREBP) [155]. Triacylglycerols, produced trought hepatic
lipogenesis, are thus sent from the liver to the blood in the form of very low-density lipoprotein
and chylomicrons.
2. HF diet triggers an increased absorption of bacterial lipopolysaccharide (LPS) (an endotoxin in the
cell wall of Gram-negative bacteria) from the gut lumen to the bloodstream inducing low-grade
inflammation, by activating B cells or dendritic cells activating and cytokine production [158].
The inflammation could also be stimulated by endotoxemia condition [157]; moreover, also the
damaged gut barrier might contribute to this metabolic endotoxaemia [159].
3. GM induces a suppression of angiopoietin-like protein 4 (ANGPTL4) in the intestinal epithelium.
ANGPTL4 is a circulating enzyme produced by liver, gut and adipose tissue that inhibits LPL;
its suppression provokes an increase of triacylglycerol storage in the adipose tissue [127].
Of note, relevant evidence suggests that both the consumption of fermentable carbohydrates and
the supplementation of SCFAs result in positive effects on host physiology and energy homeostasis.
The resistant starch (RS) is a fermentable dietary fiber used as a carbohydrate source in food. Obanda
and colleagues used obesity-prone and obesity-resistant rats to examine how weight gain and fat
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accretion relate to fermentation levels and GM after feeding RS [160]. Obese-prone rats fed with
RS at 20% of the weight of the diet did not gain more body fat than the same type of rats fed the
same diet except without the RS [160]. It could be possible that fermentation of prebiotics increased
energy expenditure but with contemporary greater energy absorption, and so without net gain in
weight and body fat. The authors hypothesized that dietary RS decreases body fat accumulation
through stimulating endogenous GLP-1 and PYY production [161]. However, the majority of these
recent researches have investigated the effect of SCFAs on animal models or in particular tissue or
metabolic process. Since SCFAs have different and parallel metabolic processes that affect energy
homeostasis, more studies are needed to bring these effects together in order to elucidate the real
impact of SCFAs [139].
3.2. Microbiome and the Brain
As previously reported, the gut microbiome affects the host’s CNS functions (as cognitive and
vegetative activities) through the MGB axis. CNS functions, vice versa, may influence the structure
of the microbiota that inhabits the intestinal lumen [112]. Several studies suggest that this mutual
interplay has a pivotal role in the occurrence of metabolic disorders, such as diabetes and obesity [162],
but also in the development of eating and stress-related neuropsychiatric disorders, including [163]
anxiety and depression.
Currently, researchers are focusing on whether the microbiome can have effects on the CNS
process and on the hedonic and homeostatic control of dietary intake [164] (Figure 2).
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Figure 2. Relations between gut microbiota and eating behavior. The gut microbiota controls the eating
behavior by several mechanisms, including changes to receptors such as taste receptors, regulation
of reward pathways, production of toxins that alter mood, and deviating neurotransmission via the
vagus nerve.
As previously described, the SCFAs produced by the microbiota have systemic effects, but they
can also directly signal to the (enteral and central) nervous system, via stimulation of the vagus nerve,
or indirectly through immune-neuroendocrine processes [158].
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The role of the vagus nerve is important in the MGB axis because it connects the 100 million
neurons of the enteric nervous system to the “nucleus tractus solitaries” [112]. The information
inserted in this communication axis is then delivered to the hypothalamus, which modulates energy
balance, appetite and dietary intake [20]. This information also includes signals from commensal
microorganisms, linking the cognitive and emotional nucleus of the CNS with peripheral gut activity,
finally leading to host eating control. Experiments showed that transection or blockade of the vagus
nerve could induce a dramatic weight loss [165]. On the other hand, vagus nerve functions appear to
drive extreme eating behavior in satiated animals when they are treated with norepinephrine [166].
The parasympathetic vagal activity was linked with weight loss also in anorexia nervosa [167],
indicating that vagal signaling, involved in the modulation of body weight, can lead to pathological
anorexia, and other CNS disorders as anxiety-depressive behaviors and autism [168,169].
The vagus nerve could be stimulated by enteroendocrine cell hormones as gut peptide YY
(PYY) and glucagon-like peptide 1 (GLP-1). The satiety hormone PYY inhibits gut motility, increases
gut transit time, and reduces appetite [170], while GLP1 decreases appetite and improves insulin
sensitivity [171]. The bacterial SCFAs could alter the release of those hormones into systemic circulation
binding to their specific enteroendocrine G-protein coupled receptors (GPRs) [172,173]. Through the
GPRs activation, SCFAs induce leptin expression, which produces the suppression of the appetite and
GLP-1 production [174]. The increased plasma GLP-1 and PYY levels inhibit ghrelin secretion [174]
and regulate appetite by releasing it into the blood stream [175]. Acetate, the main SFCA produced by
the microbiome, has a direct effect in the suppressing of appetite via central hypothalamic process [152].
The increased acetate production, due to an altered gut microbiome, induces the stimulation of the
parasympathetic nervous system with improved secretion of ghrelin, obesity and hyperphagia [145].
Lactate, another bacterial metabolite produced by Enterobacteriaceae, Lactobacilli and Bifidobacteria, is the
favorite substrate for neuronal cells and could prolong the postprandial satiety [176].
Furthermore, the microbiome can affect the central control of appetite by producing
neuroactive metabolites as tryptophan, serotonin, gamma-aminobutyric acid, endocannabinoid
ligands, and ghrelin. These bacterial metabolites are the exact analogs of the mammalian hormones
implicated in behavior and mood signaling [177]. More than half of the dopamine and the majority
of the body’s serotonin are produced at gut level [178]. Indeed, components of bacterial flora,
as Bacillus cereus, Escherichia coli [179], B. subtilis, B. mycoides, Serratia marcescens, Proteus vulgaris,
and Staphylococcus aureus [180] can produce dopamine. The probiotic B. infantis 35624 improves blood
levels of tryptophan [181], a precursor of serotonin that mediates appetite-suppressant function by the
regulation of melanocorting neurons, which control body weight homeostasis [182,183]. Moreover,
the lactic acid producing bacteria could secrete the neurochemicals histamine [184] and GABA [185] that
is involved in the regulation of feeding and energy balance [186,187]. Interestingly, GABA stimulates
the same neuroreceptors that are targeted by anti-anxiety drugs (benzodiazepines).
A few cross-sectional studies have demonstrated the association of mood alteration and anxiety
with microbiota dysbiosis [188] due to the alteration of the tryptophan metabolism [189]. Of note,
some probiotics with anti-depressive actions also showed anti-obesity effects, confirming that gut
bacteria modulation could be beneficial also for obesity-related depression [190]. The administration
of Lactobacillus helveticus reestablished the altered Firmicutes/Bacteroidetes ratio in mice with HF diet
with the contemporary reduction of anxiety-like behaviors [191]. In addition, Bifidobacterium and
Lactobacillus decreased depressive-like behaviors in association with reduced IL-6 and TNF-α level in
blood [192]. These bacterial strains could also decrease the inflammatory tone, affecting both mood
disorders and obesity. The microbiome-mediated inflammatory processes, associated with obesity,
affect the CNS, leading to important changes in several neurocircuities, including neuroendocrine
activity (impaired feedback response to cortisol) neurogenesis (impaired in the hippocampus) and
neurotransmitter metabolism (alteration in dopamine system and basal ganglia) [168]. Moreover,
the changes in feeding behavior could be attributable to dysphoria induced by the microbiome.
One potential mechanism by which dysphoria can influence eating involves bacterial virulence gene
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expression and host pain perception [193]. The production of virulence toxins often is triggered by a
low concentration of growth-limiting nutrients. Detection of simple sugars regulates virulence and
growth of several gut bacteria [194]. Microbiota could injure the gut epithelium when certain nutrients
are absent, manipulating behaviors through pain signaling [195–197] Moreover, pain perception
(nociception) requires the presence of an intestinal microbiota in mice [198], while fasting has been
shown to increase nociception by a vagal nerve mechanism [199]. In addition, some bacteria could
stimulate the endocannabinoid system, which affects gut barrier activity, host metabolism [200] and
the homoeostatic and hedonic control of appetite and food intake [201]. Brain reward signaling is
mediated by the dopaminergic mesolimbic system involved in the pathogenesis of obesity [202].
Increased colonic propionate reduces anticipatory reward responses to high-energy foods via striatal
pathways [203].
Microbiome is involved also in social behavioral alterations due to diet. An animal model study
reports that maternal high-fat diet (MHFD) induces a shift in microbial ecology that negatively
affects offspring social behavior, showing a linki between MHFD, intestinal microbiota disequilibrium,
ventral tegmental area plasticity and social behavior variations in descendants [204]. Fewer oxytocin
immunoreactive neurons in offspring hypothalamus were also observed. The administration of
Lactobacillus reuteri to the descendants was able to correct the oxytocin concentrations and social
deficits progeny.
Moreover, studies linked microbiome to the regulation of satiety and taste. One study found
that the absence of a bacterial flora in GF mice, considerably diminished expression of gut satiety
peptides. GF mice also demonstrated also impaired taste receptors for fat on gut and tongues resulting
in an augmented calorie intake from fats [128]. In addition, enteroendocrine cells expressed different
taste receptors (bitter, sweet, fat, and umami) and their activation induced secretion of GLP-1, CKK,
and ghrelin [205] In another study, GF mice preferred more sweets and showed greater numbers
of sweet taste receptors when matched to normal mice [206]. Furthermore, the oral administration
of L. acidophilus NCFM increased gut expression of opioid and cannabinoid receptors in epithelial
cell culture [207]. These findings indicate that microbiome could also affect food preferences by the
modification of receptor expression or transduction [207]. Interestingly, changes in taste receptor
expression and activity were observed after gastric bypass surgery. This procedure also induces also
gut microbiome alteration leading to satiety and food preferences changes. Several studies also indicate
a connection between cravings and the GM profile. For example, subjects who are “chocolate desiring”
showed different microbial metabolites than “chocolate indifferent” people, despite identical food
intake [208]. Finally, obesity, microbiome, and diet may also affect episodic and semantic memory [15].
Recent studies documented beneficial effects of probiotics on cognitive functions in humans [209].
On the contrary, in cohort of brain fogginess (BF) patients (consuming probiotics) with unexplained
abdominal bloating, gas, pain and distension (possibly caused by SIBO—small intestinal bacterial
overgrowth) and D-lactic acidosis, the discontinuation of probiotics along with a course of antibiotics
led to symptoms’ resolution [210]. Probably, probiotic use may increase the accumulation of bacteria
in the small intestine, resulting in disorienting brain fogginess as well as belly bloating.
3.3. The Role of Microbiome-Driven Inflammation
As widely discussed over the review, the immune system plays a crucial role in the gut–brain axis
communications since immune mediators are important messengers of this complex dialogue and,
consequently, it mechanistically links the function’s impairments in both brain and gut, as shown by
the association between chronic gut inflammation and psychological morbidity [211–214]. The immune
system plays a key role in obesity and correlated pathologies, such as in the colorectal cancer [215].
In obese patients, a chronic low-grade inflammatory state is maintained [216,217] and the peripheral
inflammation, with the activation of innate immune components (like TLRs) and the loss of intestinal
barrier integrity, can lead to neuro-inflammation. Interestingly, recent studies have demonstrated
that dysbiosis and inflammation may concur to the development of various diseases, including
Nutrients 2019, 11, 156 12 of 25
obesity and depression disorders [218]. In addition, numerous studies have now clearly confirmed
that the gut microbiome can, qualitatively and quantitatively, shape the host immune responses,
both in the gut and in systemic tissues. In this way, the GM influences the concentration and
profile of cytokines present in any given individual and, in turn, differentially affects the brain
function. For example, GF mice show numerous immune abnormalities, including impaired antibody
responses, diminished numbers of T and B lymphocytes and a defective production of cytokines
(such as IL-10, TNF-alfa, IL-6 and IL-1) [219,220]. Moreover, selective GM constituents shape specific
aspects of adaptive and innate immunity, including the differentiation of particular effector T-cell
lineages [221–223]. The obesity-associated dysbiosis is characterized by a remarkable inflammatory
potential of microbiota [224,225], which is able to activate innate and adaptive immunity in the gut
and beyond, increasing the inflammatory tone by TLRs activation and production of pro-inflammatory
cytokines [226]. Sen and colleagues have demonstrated that a dysbiotic microbiota (high sugar
diet-associated) alters the vagal gut–brain communication [208], producing an inflammatory state that
increases gut permeability. The result is the passage of LPS and pro-inflammatory cytokines from the
lumen to the lamina propria (triggering an inflammatory response) and so, microglia activation in the
nodose ganglion and finally leading to vagal remodeling [224]. Moreover, a microbiota with enhanced
pro-inflammatory activity has been demonstrated to be able to promote intestinal inflammation,
inducing colitis and metabolic syndrome [14,226]. The loss of intestinal barrier integrity, seems to be a
crucial step in the obesity pathogenesis and related diseases, including neurological disorders [219,227]
(Figure 1). In fact, the leaky gut allows the translocation of Gram-negative bacteria’s components
into the mesenteric lymph nodes and the circulation, boosting the release of pro-inflammatory
cytokines (especially TNF-alpha), via TLR2/4 direct or indirect activation [227–230], and increasing
the production of IgA and IgM [231,232]. In general the gut permeability can be considered the
direct consequence of the dysbiotic microbiota-driven local gastrointestinal inflammation [233,234],
and notably, in obese mice, the prebiotics’ supplementation can improve the gut integrity, reducing the
weight gain [235]. The leaky gut and the associated-inflammation lead to peripheral insulin resistance
and hyperglycemia, supporting the obesity establishment; moreover, the increased inflammatory
cytokines in the peripheral system can affect the BBB integrity, contributing to the development of
mood disorders [234]. Bruce-Keller and colleagues have linked obesity, microbiome, and neurologic
dysfunction, demonstrating the ability of HF diet-dysbiotic microbiota to increase inflammatory gene
expression in the medial prefrontal cortex associated with anxiety and memory impairment [236].
Moreover, the inflammation generated by HF diet-dysbiotic microbiota can activate the microglia [237],
a process observed in various neurological disorders [237–240] and associated with weight gain and
bacteria-driven hyperphagia [241].
Finally, expanding the knowledge of the mechanisms underlying the triggers of such inflammatory
responses in obesity could offer unique opportunities for intervention strategies reducing the risk of
related neurological conditions and supporting personalized treatments [242].
4. Conclusions and Future Directions
All these data suggest the presence of a deep link between the composition of the microbiota
and the development of obesity. This not only in light of the known impact of microbiome activities
on metabolic pathways and their modification, but also because the well described comorbidities,
obesity-associated (e.g., anxiety and depression), show a possible association with the activities of
the microbiome itself. This suggests several hypotheses. On the one hand, the presence of the
microbiota in all these conditions could mean that the microbiota itself is involved as a linking factor
between neuropsychological and metabolic disorders. Alternatively, the microbiota could be directly
associated with obesity and, given its impact on the nervous system, presenting a more relevant causal
role in the development of the comorbidities themselves. Still differently, the emergence of some
neuropsychological disorders could be either generated or enhanced by the microbiota modulation
and thus its functions, in relation to obesity. Finally, the most radical hypothesis is that the microbiome
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itself, due to its functional pervasiveness, may constitute a possible causal trigger of both obesity and
its comorbidities, which should therefore be reviewed and redefined in another light. In all these
scenarios, which will have to be investigated experimentally as soon as possible, it appears that the
microbiome plays a central role. Although its role is not yet fully described from a general point
of view, its impact on several levels and on multiple systems is now undeniable. In other words,
from these studies, it clearly emerges that microbiota is a sort of director, that from behind the scenes
(compared to other biological phenomena much more investigated) connects (or perhaps even directs)
elements and components of the host organism according to a more integrated, systemic perspective.
Such a systemic perspective should be intended as a methodological attitude rather than an
intrusion, performed by different experts, into other areas of investigation. As a matter of fact,
by looking at obesity as a neuropsychological disorder, does not mean to diminish the importance
of classical factors and relative approaches in the study of this important disorder. Rather, it means
embracing a more global vision of the disease (given its complexity and multifactoriality) that is,
precisely, systemic. Consequently, shifting attention to the role played by the microbiome, given its
pervasiveness and capillarity of interactions, can be a new and proficuous way to investigate the
relationships of that system and opening a new prospective for preventive and therapeutic approaches
of obesity.
Finally, future studies are needed to deep the knowledge on the mechanisms underlying the
MGB signaling and to identify the molecular pathways that could be modulated by microbiota-based
strategies. In this way, we can have new therapeutic approaches to avoid obesity and its comorbidities.
We strongly believe that additional translational and functional studies in this light will be useful to
improve targets and approaches to treat obesity and its neurological comorbidities.
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